Published in Am J Med on May 17, 2011
Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke (2014) 3.48
Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 1.31
Aspirin as adjuvant therapy for colorectal cancer--reinterpreting paradigms. Nat Rev Clin Oncol (2012) 1.26
Economic evaluation of genetic screening for Lynch syndrome in Germany. Genet Med (2015) 1.10
Aspirin in primary prevention of cardiovascular disease and cancer: a systematic review of the balance of evidence from reviews of randomized trials. PLoS One (2013) 1.03
A 16-month community-based intervention to increase aspirin use for primary prevention of cardiovascular disease. Prev Chronic Dis (2014) 0.97
Association between use of specialty dietary supplements and C-reactive protein concentrations. Am J Epidemiol (2012) 0.93
Prophylactic use of aspirin: systematic review of harms and approaches to mitigation in the general population. Eur J Epidemiol (2014) 0.91
Effect of including cancer mortality on the cost-effectiveness of aspirin for primary prevention in men. J Gen Intern Med (2013) 0.85
The impact of antiplatelet medication on hand and wrist surgery. J Hand Surg Am (2013) 0.83
Drugs for Primary Prevention of Atherosclerotic Cardiovascular Disease: An Overview of Systematic Reviews. JAMA Cardiol (2016) 0.82
Aspirin for primary prevention of cardiovascular disease. Thromb J (2015) 0.82
How confidence intervals become confusion intervals. BMC Med Res Methodol (2013) 0.81
Suitability of antiplatelet therapy in hypertensive patients. J Hum Hypertens (2014) 0.80
Population Trends in Aspirin Use for Cardiovascular Disease Prevention 1980-2009: The Minnesota Heart Survey. J Am Heart Assoc (2015) 0.80
A systematic review of aspirin in primary prevention: is it time for a new approach? Am J Cardiovasc Drugs (2015) 0.78
Use of medications and lifestyles of hypertensive patients with high risk of cardiovascular disease in rural China. PLoS One (2015) 0.78
Are the current recommendations for the use of aspirin in primary prevention of cardiovascular disease applicable in low-income countries? Vasc Health Risk Manag (2015) 0.76
Aspirin for primary prevention: a challenging decision. J Am Heart Assoc (2014) 0.75
Proteome-wide prediction of targets for aspirin: new insight into the molecular mechanism of aspirin. PeerJ (2016) 0.75
Systematic reporting bias in meta-analyses of trials of aspirin for the primary prevention of cardiovascular disease. Am J Med (2012) 0.75
Positive influence of aspirin on coronary endothelial function: Importance of the dose. World J Cardiol (2013) 0.75
Systematic reviews and meta-analyses for more profitable strategies in peripheral artery disease. Ann Med (2014) 0.75
Aspirin use in rheumatoid arthritis patients with increased risk of cardiovascular disease. ISRN Rheumatol (2013) 0.75
Effects of Aspirin on Endothelial Function and Hypertension. Curr Hypertens Rep (2016) 0.75
Community-based interventions to improve outcomes for cardiovascular disease [letter]. Prev Chronic Dis (2014) 0.75
The role of aspirin in primary prevention of vascular events. Am J Med (2012) 0.75
Neutrophil-Derived Cytosolic PLA2α Contributes to Bacterial-Induced Neutrophil Transepithelial Migration. J Immunol (2017) 0.75
Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 56.72
Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 41.47
Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med (2009) 39.97
Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 26.95
Global and regional burden of stroke during 1990-2010: findings from the Global Burden of Disease Study 2010. Lancet (2014) 10.06
Apixaban in patients with atrial fibrillation. N Engl J Med (2011) 9.97
Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 7.94
Atrial fibrillation in patients with cryptogenic stroke. N Engl J Med (2014) 6.73
A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med (2003) 6.57
Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation (2011) 6.36
Aspirin in patients undergoing noncardiac surgery. N Engl J Med (2014) 6.10
Idarucizumab for Dabigatran Reversal. N Engl J Med (2015) 5.91
Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation (2002) 5.79
Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism. JAMA (2006) 5.69
Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med (2010) 4.73
Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. Circulation (2012) 4.33
Genetic risk factors for ischaemic stroke and its subtypes (the METASTROKE collaboration): a meta-analysis of genome-wide association studies. Lancet Neurol (2012) 3.93
The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 3.75
Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med (2007) 3.74
The vexing problem of guidelines and conflict of interest: a potential solution. Ann Intern Med (2010) 3.47
Noninvasive cardiac monitoring for detecting paroxysmal atrial fibrillation or flutter after acute ischemic stroke: a systematic review. Stroke (2007) 3.33
The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study. Circulation (2013) 2.64
American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Circulation (2003) 2.52
Causes of death and influencing factors in patients with atrial fibrillation: a competing-risk analysis from the randomized evaluation of long-term anticoagulant therapy study. Circulation (2013) 2.48
Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial. Ann Intern Med (2011) 2.45
IScore: a risk score to predict death early after hospitalization for an acute ischemic stroke. Circulation (2011) 2.29
Clonidine in patients undergoing noncardiac surgery. N Engl J Med (2014) 2.07
Processed residual pump blood in cardiac surgery: the Processed Residual Blood in Cardiac surgery trial. Transfusion (2012) 2.02
Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 1.97
Escalating levels of access to in-hospital care and stroke mortality. Stroke (2008) 1.97
Increased risk of cognitive and functional decline in patients with atrial fibrillation: results of the ONTARGET and TRANSCEND studies. CMAJ (2012) 1.86
Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial. Circulation (2012) 1.83
Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial. Lancet Neurol (2012) 1.76
Suboptimal monitoring and dosing of unfractionated heparin in comparative studies with low-molecular-weight heparin. Ann Intern Med (2003) 1.75
Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 1.74
An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Arch Intern Med (2003) 1.70
American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. J Am Coll Cardiol (2003) 1.67
Use of antifibrinolytic therapy to reduce transfusion in patients undergoing orthopedic surgery: a systematic review of randomized trials. Thromb Res (2008) 1.64
Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable. Ann Intern Med (2011) 1.56
Is impaired renal function a contraindication to the use of low-molecular-weight heparin? Arch Intern Med (2002) 1.55
Beyond unfractionated heparin and warfarin: current and future advances. Circulation (2007) 1.52
Challenges of establishing new antithrombotic therapies in atrial fibrillation. Circulation (2007) 1.52
Variables associated with 7-day, 30-day, and 1-year fatality after ischemic stroke. Stroke (2008) 1.51
Evaluation of a venous-return assist device to treat severe post-thrombotic syndrome (VENOPTS). A randomized controlled trial. Thromb Haemost (2008) 1.50
Translational success stories: development of direct thrombin inhibitors. Circ Res (2012) 1.49
Heparin-induced skin lesions and other unusual sequelae of the heparin-induced thrombocytopenia syndrome: a nested cohort study. Chest (2005) 1.49
Guidelines for anticoagulant use in acute coronary syndromes. Lancet (2008) 1.49
Myocardial injury after noncardiac surgery: a large, international, prospective cohort study establishing diagnostic criteria, characteristics, predictors, and 30-day outcomes. Anesthesiology (2014) 1.47
Does acetyl salicylic acid (ASA) have a role in the prevention of venous thromboembolism? Br J Haematol (2009) 1.46
The prevalence of vertebral fracture on vertebral fracture assessment imaging in a large cohort of patients with rheumatoid arthritis. Rheumatology (Oxford) (2013) 1.46
Pexelizumab does not "complement" percutaneous coronary intervention in patients with ST-elevation myocardial infarction. JAMA (2007) 1.45
Direct thrombin inhibitors in acute coronary syndromes: effect in patients undergoing early percutaneous coronary intervention. Eur Heart J (2005) 1.42
Should patients with stroke wear compression stockings to prevent venous thromboembolism? Ann Intern Med (2010) 1.42
Comparative efficacy and safety of anticoagulant strategies for acute coronary syndromes. Comprehensive network meta-analysis of 42 randomised trials involving 117,353 patients. Thromb Haemost (2015) 1.40
Use of antithrombotic agents during pregnancy: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 1.39
Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran. Thromb Haemost (2015) 1.36
Temporal trends in prevention of venous thromboembolism following primary total hip or knee arthroplasty 1996-2001: findings from the Hip and Knee Registry. Chest (2003) 1.36
Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. Eur Heart J (2004) 1.34
Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future. Nat Clin Pract Cardiovasc Med (2008) 1.33
Prevalence of cardiovascular risk factors in the Middle East: a systematic review. Eur J Cardiovasc Prev Rehabil (2009) 1.33
Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 1.31
A diagnostic strategy involving a quantitative latex D-dimer assay reliably excludes deep venous thrombosis. Ann Intern Med (2003) 1.21
New antithrombotic drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 1.21
Supporting the improvement and management of prescribing for urinary tract infections (SIMPle): protocol for a cluster randomized trial. Trials (2013) 1.19
Albuminuria and decline in cognitive function: The ONTARGET/TRANSCEND studies. Arch Intern Med (2011) 1.14
New anticoagulants. Blood (2004) 1.13
Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment. Am Heart J (2010) 1.11
Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, Part 1: Prevention. Am J Hematol (2009) 1.11
Genetic determinants of dabigatran plasma levels and their relation to bleeding. Circulation (2013) 1.10
Controversies in timing of the first dose of anticoagulant prophylaxis against venous thromboembolism after major orthopedic surgery. Chest (2003) 1.08
Establishing an optimal therapeutic range for coumarins: filling in the gaps. Arch Intern Med (2004) 1.07
Assessment of anticoagulation intensity and management of bleeding with old and new oral anticoagulants. Can J Cardiol (2013) 1.05
Stroke risk and efficacy of apixaban in atrial fibrillation patients with moderate chronic kidney disease. J Stroke Cerebrovasc Dis (2012) 1.05
Tackling the global burden of stroke: the need for large-scale international studies. Lancet Neurol (2009) 1.04
The effect of blood storage duration on in-hospital mortality: a randomized controlled pilot feasibility trial. Transfusion (2012) 1.03
Relationship between baseline haemoglobin and major bleeding complications in acute coronary syndromes. Eur Heart J (2009) 1.02
Reliability of proxy respondents for patients with stroke: a systematic review. J Stroke Cerebrovasc Dis (2010) 1.01
Pacemaker-detected atrial fibrillation in patients with pacemakers: prevalence, predictors, and current use of oral anticoagulation. Can J Cardiol (2012) 0.97
Early cerebral small vessel disease and brain volume, cognition, and gait. Ann Neurol (2015) 0.96
A cohort study examination of established and emerging risk factors for atrial fibrillation: the Busselton Health Study. Eur J Epidemiol (2014) 0.94
Monitoring unfractionated heparin with the aPTT: time for a fresh look. Thromb Haemost (2006) 0.93
Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa). Eur Heart J (2013) 0.92
Reduction of out-of-hospital symptomatic venous thromboembolism by extended thromboprophylaxis with low-molecular-weight heparin following elective hip arthroplasty: a systematic review. Arch Intern Med (2003) 0.92
Major bleeding, mortality, and efficacy of fondaparinux in venous thromboembolism prevention trials. Circulation (2009) 0.90
Relationship of activated partial thromboplastin time to coronary events and bleeding in patients with acute coronary syndromes who receive heparin. Circulation (2003) 0.90
The effect of long-term homocysteine-lowering on carotid intima-media thickness and flow-mediated vasodilation in stroke patients: a randomized controlled trial and meta-analysis. BMC Cardiovasc Disord (2008) 0.90
Dabigatran attenuates thrombin generation to a lesser extent than warfarin: could this explain their differential effects on intracranial hemorrhage and myocardial infarction? J Thromb Thrombolysis (2013) 0.89